Biosimilars Pipeline (Oncology Focus)
Oncology
Key Facts
About Aurobindo Pharma
Founded in 1986, Aurobindo Pharma has grown from an API manufacturer into a global generics powerhouse with a mission to make medicines affordable and accessible worldwide. Its core strategy leverages deep vertical integration, significant manufacturing scale (29 facilities producing 50+ billion formulation units annually), and a strategic pivot towards high-value complex generics, injectables, and biosimilars. Key achievements include a portfolio of over 830 ANDA filings in the US with 600+ approvals, leadership in antiretroviral therapies, and the recent inauguration of a flagship Penicillin-G facility, underscoring its commitment to backward integration and supply chain resilience.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |